Azenta Inc reported a mixed Q2 2025, with revenue of $143.4 million, down 9.9% year-over-year and 2.8% sequentially. The gross margin held firm at 45.9%, but operating profitability deteriorated into a mid-teens million negative, delivering an operating loss of $16.2 million and a net loss of $40.5 million, or -28.2% of revenue. EBITDA was modestly positive at $1.38 million, yet significant non-cash and non-operating items (notably depreciation and amortization totaling ~$13.95 million and other adjustments) contributed to the bottom-line weakness. Despite the bottom-line softness, Azenta generated positive operating cash flow of $13.6 million and free cash flow of $7.0 million, supported by a strong balance sheet and liquidity cushion. The company ended the period with net cash of nearly $200 million and a solid current ratio of 3.22, underscoring financial flexibility to fund growth initiatives and ongoing R&D.
Strategically, Azenta continues to pursue growth across its Life Sciences Products and Life Sciences Services segments, aiming to monetize outsourcing demand, sample management, cold chain, and informatics capabilities. Near-term pressures center on profitability normalization as the company scales its services offerings and optimizes operating costs, while longer-term catalysts include expanding addressable markets in biobanking, genomics workflows, and international expansions. Management commentary (where available) suggests a focus on operating leverage and portfolio optimization, though formal forward guidance for 2025 was not disclosed in the provided data.